1Ramos-Casals M, Tzioufas AG, Font J. Primary Sj6gren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis, 2005,64 (3) :347-354.
2Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjfigren's syndrome: a revised version of the European criteria pro- posed by the American-European Consensus Group. Ann Rheum Dis,2002.61 (6) :554-558.
3Vitali C, Bombarclieri S, Moutsopoulos HM, et al. Preliminary crite- ria for the classification of Sjtigren's syndrome. Results of a prospec- tive concerted action supported by the European Community. Arthri- tis Rheum, 1993,36 (3) :340-347.
4Fries JF, Hochberg MC, Medsger TA Jr, et al. Criteria for rheumatic disease. Different types and different functions. The American Col- lege of Rheumatology Diagnostic and Therapeutic Criteria Commit- tee. Arthritis Rheum, 1994,37 (4) :454-462.
5Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The manage- ment of SjSgren's syndrome. Nat Clin Pract Rheumatol, 2006,2 (5) :252-261.
6van Rossum M, van Soesbergen R, de Kort S, et al. Anti-cyclic cit- rullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumato1,2003,30 (g) : 825-828.
8Feist E, Hermann KG, Dankof A. [ Vasculopathy in Sjfigren's syn- drome ]. Z Rheumatol,2009,68 (4) :305-311.
9Kroot E J, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent- onset rheumatoid arthritis. Arthritis Rheum, 2000,43 ( 8 ) : 1831- 1835.
10Brito-Zer6n P, Ramos-Casals M. [ Prognosis of patients with primary SjOgren's syndrome ]. Med Clin (Barc) ,2008,130 (3) : 109-115.
二级参考文献38
1Sahin M, Duzgun N, Tunc SE, et al. Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus:is there an association? Clin Rheumatol,2007 ,26 :154-160.
2Vlachoyiannopoulos PG, Samarkos M, Sikara M, et al. Antiphospholipid antibodies:Iaboratory and pathogenetic aspects. Crit Rev CIin Lab Sci, 2007,44 : 271-338.
3Asherson RA, Fei HM, Staub HL, et al. Antiphospholipid antibodies and HLA associations in primary Sjogren's syndrome. Ann Rheum Dis, 1992,51:495498.
4Rosler DH, Conway MD, Anaya JM, et al. Ischemic optic neuropathy and high-level anticardiolipin antibodies in primary Sjtlgren's syndrome. Lupus, 1995,4 : 155-157.
5Mochizuki H, Okano M, Masaki T, et al. A case of Sjogren's syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism. Rinsho Shinkeigaku, 1997,37:57-59.
6Tumiati B, Casoli P, Parmeggiani A. Hearing loss in the Sjogren syndrome. Ann Intern Med, 1997,126:450-453.
7Puszczewicz M, Zimmermann-Gorska I, Bialkowska-Puszczewicz G. Prevalence of antiphospholipid antibodies in patients with primary Sjogren's syndrome. Pol Arch Med Wewn ,2006,115:414-416.
8Pennec YL, Magadur G, Jouquan J, et al. Serial measurements of anticardiolipin antibodies in primary Sjisgren's syndrome. Clin Exp Rheumatol, 1991,9:165-167.
9Jedryka-Goral A, Jagiello P, D Cruz DP, et al. Isotype profile and clinical relevance of anticardiolipin antibodies in Sjogren's syndrome. Ann Rheum Dis, 1992,51 : 889-891.
10Cervera R, Garcia-Carrasco M, Font J, et al. Antiphospholipid antibodies in primary Sjogren's syndrome:prevalence and clinical signifieance in a series of 80 patients. Clin Exp Rheumatol, 1997,15:361-365.
4Papiris S A, Tsonis I A, Moutsopoulos H M. Sjogreng syn- drome[J]. Semin Respir Crit Care Med, 2007,28(4):459471.
5Fehsan T, Stanko P, Mracna J. Sjogren syndrome in pres- ent[J]. Bratisl Lek Listy, 2012,113(8):514-516.
6Voulgarelis M, Moutsopoulos H M. Mucosa-associated lymph- oid tissue lymphoma in Sjogren s syndrome: risks, manage- ment, and prognosis[J]. Rheum Dis Clin North Am, 2008,34 (4) :921-933.
7Ebert E C. Gastrointestinal and hepatic manifestations of Sjogren syndrome [ J ]. J Clin Gastroenterol, 2012,46( 1 ) :25-30.
8Koga H, Shimizu K, Tarumi K, et al. Rectal mucosal pro- lapse syndrome as an unusual gastrointestinal manifestation of Sjogreng syndrome: a case report[J]. J Med Case Rep, 2009,3:85.
9Nagashima T, Hoshino M, Shimoji S, et al. Protein-losing gastroenteropathy associated with primary Sjogren "s syn- drome: a characteristic oriental variant [ J ]. Rheumatol Int, 2009,29(7) :817-820.
10Park K, Haberberger R V, Gordon T P, et al. Antibodies interfering with the type 3 muscarinic receptor pathway in- hibit gastrointestinal motility and cholinergic neurotransmis- sion in Sjogren's syndrome [ J ]. Arthritis Rheum, 2011,63 (5) :1426-1434.
